Contrast-Enhanced Photon-Counting Detector CT (PCD-CT) for the Local Staging of Rectal Cancer
About this study
This study evaluates whether images taken using a photon counting detector CT scanner (PCD-CT) can determine the growth of rectal cancer as well as, or better than, MRI for the management of patients with rectal cancer.
- Condition
- Rectal Carcinoma
- Tested
- PCD-CT
- Sponsor
- Mayo Clinic
Who can join
- Age
- 18 to 99 years
- Sex
- All sexes
- Healthy volunteers
- Not accepted
Inclusion 8
- Minimum age: 18 years
- Maximum age: 99 years
- Study condition: Rectal Carcinoma
- Adult patients 18 to 99 years of age
- Patients with proven rectal cancer clinically referred for staging pelvic MRI and contrast-enhanced CT of the abdomen and pelvis (for evaluation of liver and peritoneal disease)
- Endoscopic or imaging report that tumor is 2 cm or larger
- Patients who are able and willing to sign the informed consent
- Negative pregnancy test if subject is of child-bearing age (females of child-bearing potential will be screened for pregnancy using a urine pregnancy test, which will be administered by the unit study coordinator at no cost to the patient)
Exclusion 8
- Minors less than 18 years old
- Patient unable to provide written informed consent
- Pregnancy
- Estimated Glomerular Filtration Rate (eGFR) ≤ 60
- History of prior moderate or severe contrast reaction including unresponsiveness, severe respiratory distress, convulsions, arrhythmia, cardiopulmonary distress, progressive angioedema, laryngeal edema, dyspnea, bronchospasm, symptomatic tachycardia, symptomatic bradycardia, hypotension, hypertensive crisis
- Any history of premedication prior to iodinated contrast
- Bilateral hip replacement/prosthesis
- Patients that consent to participation but do not undergo their clinically indicated MRI scanning for any reason (e.g., bad IV, infiltration, reaction, change in indication)
Where
1 site, 1 recruiting
Mayo Clinic in Rochester
Rochester, Minnesota, United States
Contact
-
Clinical Trials Referral Office
855-776-0015 mayocliniccancerstudies@mayo.edu
-
Boleyn Andrist
507-538-7752 andrist.boleyn@mayo.edu
Potential match only. Final eligibility is determined by the study team.